Wedbush Has Bearish Estimate for ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities researchers at Wedbush reduced their FY2024 earnings estimates for shares of Artiva Biotherapeutics in a research report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($5.08) for the year, down from their previous estimate of ($4.55). Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.60) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.76) EPS and FY2027 earnings at ($2.91) EPS.

ARTV has been the subject of a number of other research reports. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating and a $21.00 price objective for the company. TD Cowen began coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating for the company. Cantor Fitzgerald began coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $21.25.

Artiva Biotherapeutics Trading Down 4.3 %

NASDAQ:ARTV opened at $10.06 on Friday. Artiva Biotherapeutics has a 1-year low of $9.68 and a 1-year high of $17.31. The stock has a 50-day simple moving average of $12.57.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ARTV. BNP Paribas Financial Markets bought a new position in shares of Artiva Biotherapeutics in the third quarter worth about $42,000. MetLife Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth $135,000. Barclays PLC bought a new position in shares of Artiva Biotherapeutics during the third quarter worth $304,000. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $623,000. Finally, Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $680,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.